

## Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQX: LVCLY

## ASX ANNOUNCEMENT

### Results of the Annual General Meeting held on 19 November 2013

**19 November 2013: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)**, the following voting results in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

#### Resolution 1: Adoption of Remuneration Report

"That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Directors' Report of the Company, for the year ended 30 June 2013 be adopted, details of which are set out in the explanatory notes to resolution 1 in the notice of meeting."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
72,441,337	507,696	9,600	370,000

#### Resolution 2: Re-election of Mr Laurie Hunter as a Director

"That Mr Laurie Hunter, being a Director of the Company, retires by rotation in accordance with the Constitution and, being eligible, offers himself for re-election, be re-elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 2 in the notice of meeting."

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
72,486,312	411,000	17,750	413,571

**Resolution 3: Re-election of Mr Robert Willcocks as a Director**

“That Mr Robert Willcocks, being a Director of the Company, retires by rotation in accordance with the Constitution and, being eligible, offers himself for re-election, be re-elected as a Director of the Company, details of which are set out in the explanatory notes to resolution 3 in the notice of meeting.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
72,486,312	411,000	17,750	413,571

**SPECIAL BUSINESS**

**Resolution 4: Approval to Exempt from Listing Rule 7.1 Options Issued Under the Employee Share Option Plan**

“That for the purposes of ASX Listing Rule 7.2 (exception 9), the issue of options under the Company’s Employee Share Option Plan, on the terms and conditions set out in the explanatory notes to resolution 4 in the notice of meeting, be approved as an exception to ASX Listing Rule 7.1.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
72,288,460	509,986	160,187	-

**Resolution 5: Approval of issue of options to Dr Andrea Grant or her nominee in accordance with Listing Rule 10.11**

“That approval be given, pursuant to ASX Listing Rule 10.11, for the issue of 100,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.10 per share; and 100,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.15 per share; to Andrea Grant or her nominee, details of which are set out in the explanatory notes to resolution 5 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
47,291,750	464,125	25,159,187	413,571

**Resolution 6 Approval of issue of options to Professor Robert Elliott or his nominee in accordance with Listing Rule 10.11**

“That approval be given, pursuant to ASX Listing Rule 10.11, for the issue of 100,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.10 per share; and 100,000 unlisted options over ordinary shares at a nil issue price and an exercise price of \$0.15 per share; to Robert Elliott or his nominee, details of which are set out in the explanatory notes to resolution 6 in the notice of meeting”.

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION
47,276,750	479,125	25,159,187	413,571

– Ends –

For further information: [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the company:</b> Dr Andrea Grant Managing Director Tel: +64 9 270 7941 Mobile: +64 21 078 5421 <a href="mailto:agrant@lctglobal.com">agrant@lctglobal.com</a></p> <p><b>Company Secretary:</b> Nick Geddes Tel: +61 1300 134 875</p>	<p><b>Media enquires – NZ:</b> Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 <a href="mailto:rachaelj@botica.co.nz">rachaelj@botica.co.nz</a></p> <p><b>Media enquiries – Australia &amp; World</b> Shevaun Cooper Buchan Consulting Tel: +61 3 9866 4722 Mobile: +61 421 760 775 <a href="mailto:scooper@buchanwe.com.au">scooper@buchanwe.com.au</a></p>
---	--

**About Living Cell Technologies**

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need. To date, the company has taken two therapeutic candidates into clinical development: DIABECCELL® for the treatment of Type 1 diabetes and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease.

Through an innovative joint venture with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECCELL and the Phase I clinical trials of NTCELL in Parkinson’s disease. LCT retains a 50% share of future profits from DIABECCELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the DOL partnership.

LCT's unique, proprietary technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter

#### **LCT disclaimer**

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*